Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. NuCana plc
  6. Summary
    NCNA   US67022C1062

NUCANA PLC

(NCNA)
  Report
Delayed Nasdaq  -  03:58 2022-10-05 pm EDT
1.002 USD   +0.16%
10/03Nucana : Presentation - October 2022
PU
09/26European ADRs Decline in Monday Trading
MT
09/23European ADRs Fall in Friday Trading
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/29/2022 09/30/2022 10/03/2022 10/04/2022 10/05/2022 Date
1.02(c) 1.045(c) 1.02(c) 1(c) 1.0016(c) Last
92 867 100 019 99 407 99 381 76 770 Volume
+2.00% +2.45% -2.39% -1.96% +0.16% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -29,7 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,84x
Yield 2022 -
Sales 2023 - - -
Net income 2023 -26,2 M - -
Net Debt 2023 - - -
P/E ratio 2023 -2,40x
Yield 2023 -
Capitalization 51,8 M 51,8 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 32
Free-Float 99,0%
More Financials
Company
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatments for cancer patients using its ProTide technology. ProTide are designed to overcome cancer resistance mechanism and generate anti-cancer metabolites in cancer cells. The Company's pipeline includes Acelari, , NUC-3373, and NUC-7738. Its ProTide candidates Acelari and NUC-3373 are chemical... 
More about the company
Ratings of NuCana plc
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about NUCANA PLC
10/03Nucana : Presentation - October 2022
PU
09/26European ADRs Decline in Monday Trading
MT
09/23European ADRs Fall in Friday Trading
MT
09/22European ADRs Move Lower in Thursday Trading
MT
09/22Jefferies & Co. Adjusts NuCana's Price Target to $3 From $21, Keeps Buy Rating
MT
09/21European ADRs Move Lower in Wednesday Trading
MT
09/19European ADRs Move Lower in Monday Trading
MT
09/15European ADRs Move Lower in Thursday Trading
MT
09/14European ADRs Move Slightly Higher in Wednesday Trading
MT
09/13European ADRs Drop Sharply in Tuesday Trading
MT
09/12NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology ..
GL
09/12NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology ..
AQ
09/12Nucana Presents Promising Data on NUC-7738 At the European Society of Medical Oncology ..
CI
09/12NuCana Presents Favorable Data on NUC-3373 at the European Society of Medical Oncology ..
GL
09/12NuCana Presents Favorable Data on NUC-3373 at the European Society of Medical Oncology ..
AQ
More news
News in other languages on NUCANA PLC
09/26Les ADR européens baissent dans la négociation de lundi
09/23Les ADR européens chutent dans les échanges de vendredi
09/22Les ADR européens sont en baisse jeudi
09/21Les ADR européens sont en baisse mercredi
09/19Les ADR européens sont en baisse lundi
More news
Analyst Recommendations on NUCANA PLC
More recommendations
Chart NUCANA PLC
Duration : Period :
NuCana plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NUCANA PLC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 1,00 $
Average target price 4,26 $
Spread / Average Target 325%
EPS Revisions
Managers and Directors
Hugh Stephen Griffith Chief Executive Officer & Executive Director
Donald Munoz Chief Financial Officer
Andrew Martin Kay Non-Executive Chairman
Theresa Margaret Bruce Senior Vice President-Clinical Operations
Elisabeth Oelmann Senior VP-Medical & Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
NUCANA PLC-57.92%52
REGENERON PHARMACEUTICALS, INC.18.08%79 063
VERTEX PHARMACEUTICALS37.53%77 102
BIONTECH SE-46.64%33 432
WUXI APPTEC CO., LTD.-39.54%29 067
GENMAB A/S0.76%23 187